Compare AMPH & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPH | TNDM |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.8M | 1.1B |
| IPO Year | 2005 | 2013 |
| Metric | AMPH | TNDM |
|---|---|---|
| Price | $19.03 | $15.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 19 |
| Target Price | ★ $28.38 | $28.00 |
| AVG Volume (30 Days) | 614.5K | ★ 2.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | $719,887,000.00 | ★ $1,014,736,000.00 |
| Revenue This Year | $6.90 | $8.11 |
| Revenue Next Year | $4.64 | $11.85 |
| P/E Ratio | $139.07 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $16.65 | $10.00 |
| 52 Week High | $31.26 | $29.65 |
| Indicator | AMPH | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 40.98 |
| Support Level | $18.92 | $11.86 |
| Resistance Level | $19.81 | $15.75 |
| Average True Range (ATR) | 0.76 | 1.24 |
| MACD | 0.08 | -0.16 |
| Stochastic Oscillator | 41.78 | 0.28 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.